APO RESEARCH · REPORT
Mesalazine
This report study Mesalamine API market, Mesalamine API is off white to creamish colored powder. Mesalazine was approved for medical use in the United States in 1987.
Product & engineering
Understand the product.
This report study Mesalamine API market, Mesalamine API is off white to creamish colored powder. Mesalazine was approved for medical use in the United States in 1987.
Mesalazine also known as mesalamine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
Selected research
Industry Research
Mesalazine Industry Research Report 2026
Market perspective
This report study Mesalamine API market, Mesalamine API is off white to creamish colored powder. Mesalazine was approved for medical use in the United States in 1987.
Mesalazine also known as mesalamine, or 5-aminosalicylic acid (5-ASA), is a medication used to treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease. It is generally used for mildly to moderately severe disease. It is taken by mouth or rectally. The formulations which are taken by mouth appear to be similarly effective.
The industry's leading manufacturers are Syntese A/S, PharmaZell and Cambrex Corporation etc. The top 3 companies hold a share over 50%. In terms of regions, the revenue share in Europe is the highest, reaching 43% in 2021, followed by Asia Pacific with a share about 31%.
Read the full market overview
Report Scope
This report quantifies the global Mesalazine market in terms of revenue (US$ million) and, where applicable, sales volume (Ton), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/Ton) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Mesalazine Market by Company
PharmaZell
Syntese A/S
Cambrex Corporation
Divis Laboratories
Chemi SpA
Ipca Laboratories
Hangzhou Brother
Lianyungang Fengheng Biopharm
Lasa Loboratory
Corden Pharma Bergamo
Erregierre SpA
CTX Lifescience
Ishita Active Pharma Ingredients
YC Biotech (Jiangsu)
Xinxiang Tianfeng Fine Chemical
Mesalazine Segment by Purity
Above 97 %
Above 98 %
Above 99 %
Mesalazine Segment by Application
Tablets
Capsules
Pellet and Granule
Suppository
Enema
Others
Mesalazine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mesalazine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Mesalazine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mesalazine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Mesalazine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Mesalazine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Mesalazine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by purity, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Above 97 %
- Above 98 %
- Above 99 %
Applications
- Tablets
- Capsules
- Pellet and Granule
- Suppository
- Enema
- Others
Companies covered
- PharmaZell
- Syntese A/S
- Cambrex Corporation
- Divis Laboratories
- Chemi SpA
- Ipca Laboratories
- Hangzhou Brother
- Lianyungang Fengheng Biopharm
- Lasa Loboratory
- Corden Pharma Bergamo
- Erregierre SpA
- CTX Lifescience
- Ishita Active Pharma Ingredients
- YC Biotech (Jiangsu)
- Xinxiang Tianfeng Fine Chemical
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Mesalazine Market Size (2021-2032)
- 2.2.2 Global Mesalazine Sales (2021-2032)
- 2.2.3 Global Mesalazine Market Average Price (2021-2032)
- 2.3 Mesalazine by Purity
- 2.3.1 Market Value Comparison by Purity (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Above 97 %
- 2.3.3 Above 98 %
- 2.3.4 Above 99 %
- 2.4 Mesalazine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Tablets
- 2.4.3 Capsules
- 2.4.4 Pellet and Granule
- 2.4.5 Suppository
- 2.4.6 Enema
- 2.4.7 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Mesalazine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Mesalazine Sales (Ton) of Manufacturers (2021-2026)
- 3.3 Global Mesalazine Revenue of Manufacturers (2021-2026)
- 3.4 Global Mesalazine Average Price by Manufacturers (2021-2026)
- 3.5 Global Mesalazine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Mesalazine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Mesalazine, Product Type & Application
- 3.8 Global Manufacturers of Mesalazine, Established Date
- 3.9 Global Mesalazine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 PharmaZell
- 4.1.1 PharmaZell Company Information
- 4.1.2 PharmaZell Business Overview
- 4.1.3 PharmaZell Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 PharmaZell Mesalazine Product Portfolio
- 4.1.5 PharmaZell Recent Developments
- 4.2 Syntese A/S
- 4.2.1 Syntese A/S Company Information
- 4.2.2 Syntese A/S Business Overview
- 4.2.3 Syntese A/S Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Syntese A/S Mesalazine Product Portfolio
- 4.2.5 Syntese A/S Recent Developments
- 4.3 Cambrex Corporation
- 4.3.1 Cambrex Corporation Company Information
- 4.3.2 Cambrex Corporation Business Overview
- 4.3.3 Cambrex Corporation Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Cambrex Corporation Mesalazine Product Portfolio
- 4.3.5 Cambrex Corporation Recent Developments
- 4.4 Divis Laboratories
- 4.4.1 Divis Laboratories Company Information
- 4.4.2 Divis Laboratories Business Overview
- 4.4.3 Divis Laboratories Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Divis Laboratories Mesalazine Product Portfolio
- 4.4.5 Divis Laboratories Recent Developments
- 4.5 Chemi SpA
- 4.5.1 Chemi SpA Company Information
- 4.5.2 Chemi SpA Business Overview
- 4.5.3 Chemi SpA Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Chemi SpA Mesalazine Product Portfolio
- 4.5.5 Chemi SpA Recent Developments
- 4.6 Ipca Laboratories
- 4.6.1 Ipca Laboratories Company Information
- 4.6.2 Ipca Laboratories Business Overview
- 4.6.3 Ipca Laboratories Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Ipca Laboratories Mesalazine Product Portfolio
- 4.6.5 Ipca Laboratories Recent Developments
- 4.7 Hangzhou Brother
- 4.7.1 Hangzhou Brother Company Information
- 4.7.2 Hangzhou Brother Business Overview
- 4.7.3 Hangzhou Brother Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Hangzhou Brother Mesalazine Product Portfolio
- 4.7.5 Hangzhou Brother Recent Developments
- 4.8 Lianyungang Fengheng Biopharm
- 4.8.1 Lianyungang Fengheng Biopharm Company Information
- 4.8.2 Lianyungang Fengheng Biopharm Business Overview
- 4.8.3 Lianyungang Fengheng Biopharm Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Lianyungang Fengheng Biopharm Mesalazine Product Portfolio
- 4.8.5 Lianyungang Fengheng Biopharm Recent Developments
- 4.9 Lasa Loboratory
- 4.9.1 Lasa Loboratory Company Information
- 4.9.2 Lasa Loboratory Business Overview
- 4.9.3 Lasa Loboratory Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Lasa Loboratory Mesalazine Product Portfolio
- 4.9.5 Lasa Loboratory Recent Developments
- 4.10 Corden Pharma Bergamo
- 4.10.1 Corden Pharma Bergamo Company Information
- 4.10.2 Corden Pharma Bergamo Business Overview
- 4.10.3 Corden Pharma Bergamo Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Corden Pharma Bergamo Mesalazine Product Portfolio
- 4.10.5 Corden Pharma Bergamo Recent Developments
- 4.11 Erregierre SpA
- 4.11.1 Erregierre SpA Company Information
- 4.11.2 Erregierre SpA Business Overview
- 4.11.3 Erregierre SpA Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Erregierre SpA Mesalazine Product Portfolio
- 4.11.5 Erregierre SpA Recent Developments
- 4.12 CTX Lifescience
- 4.12.1 CTX Lifescience Company Information
- 4.12.2 CTX Lifescience Business Overview
- 4.12.3 CTX Lifescience Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 CTX Lifescience Mesalazine Product Portfolio
- 4.12.5 CTX Lifescience Recent Developments
- 4.13 Ishita Active Pharma Ingredients
- 4.13.1 Ishita Active Pharma Ingredients Company Information
- 4.13.2 Ishita Active Pharma Ingredients Business Overview
- 4.13.3 Ishita Active Pharma Ingredients Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Ishita Active Pharma Ingredients Mesalazine Product Portfolio
- 4.13.5 Ishita Active Pharma Ingredients Recent Developments
- 4.14 YC Biotech (Jiangsu)
- 4.14.1 YC Biotech (Jiangsu) Company Information
- 4.14.2 YC Biotech (Jiangsu) Business Overview
- 4.14.3 YC Biotech (Jiangsu) Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 YC Biotech (Jiangsu) Mesalazine Product Portfolio
- 4.14.5 YC Biotech (Jiangsu) Recent Developments
- 4.15 Xinxiang Tianfeng Fine Chemical
- 4.15.1 Xinxiang Tianfeng Fine Chemical Company Information
- 4.15.2 Xinxiang Tianfeng Fine Chemical Business Overview
- 4.15.3 Xinxiang Tianfeng Fine Chemical Mesalazine Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Xinxiang Tianfeng Fine Chemical Mesalazine Product Portfolio
- 4.15.5 Xinxiang Tianfeng Fine Chemical Recent Developments
5 Global Mesalazine Market Scenario by Region
- 5.1 Global Mesalazine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Mesalazine Sales by Region: 2021-2032
- 5.2.1 Global Mesalazine Sales by Region: 2021-2026
- 5.2.2 Global Mesalazine Sales by Region: 2027-2032
- 5.3 Global Mesalazine Revenue by Region: 2021-2032
- 5.3.1 Global Mesalazine Revenue by Region: 2021-2026
- 5.3.2 Global Mesalazine Revenue by Region: 2027-2032
- 5.4 North America Mesalazine Market Facts & Figures by Country
- 5.4.1 North America Mesalazine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Mesalazine Sales by Country (2021-2032)
- 5.4.3 North America Mesalazine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Mesalazine Market Facts & Figures by Country
- 5.5.1 Europe Mesalazine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Mesalazine Sales by Country (2021-2032)
- 5.5.3 Europe Mesalazine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Mesalazine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Mesalazine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Mesalazine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Mesalazine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Mesalazine Market Facts & Figures by Country
- 5.7.1 South America Mesalazine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Mesalazine Sales by Country (2021-2032)
- 5.7.3 South America Mesalazine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Mesalazine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Mesalazine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Mesalazine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Mesalazine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Purity
- 6.1 Global Mesalazine Sales by Purity (2021-2032)
- 6.1.1 Global Mesalazine Sales by Purity (2021-2032) & (Ton)
- 6.1.2 Global Mesalazine Sales Market Share by Purity (2021-2032)
- 6.2 Global Mesalazine Revenue by Purity (2021-2032)
- 6.2.1 Global Mesalazine Sales by Purity (2021-2032) & (US$ Million)
- 6.2.2 Global Mesalazine Revenue Market Share by Purity (2021-2032)
- 6.3 Global Mesalazine Price by Purity (2021-2032)
7 Segment by Application
- 7.1 Global Mesalazine Sales by Application (2021-2032)
- 7.1.1 Global Mesalazine Sales by Application (2021-2032) & (Ton)
- 7.1.2 Global Mesalazine Sales Market Share by Application (2021-2032)
- 7.2 Global Mesalazine Revenue by Application (2021-2032)
- 7.2.1 Global Mesalazine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Mesalazine Revenue Market Share by Application (2021-2032)
- 7.3 Global Mesalazine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Mesalazine Value Chain Analysis
- 8.1.1 Mesalazine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Mesalazine Production Mode & Process
- 8.2 Mesalazine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Mesalazine Distributors
- 8.2.3 Mesalazine Customers
9 Global Mesalazine Analyzing Market Dynamics
- 9.1 Mesalazine Industry Trends
- 9.2 Mesalazine Industry Drivers
- 9.3 Mesalazine Industry Opportunities and Challenges
- 9.4 Mesalazine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst